AOP Orphan and Bioprojet Pharma SAS entered a distribution agreement for Wakix®

SENDER

AOP Orphan Pharmaceuticals Aktiengesellschaft
Contact:
AOP
Phone: +43 503 72 44-24
E-Mail: olena.weissenbacher@aoporphan.com

Further Releases

AOP Orphan reports full validity of arbitral award against PharmaEssentia

BESREMi® (Ropeginterferon?alfa-2b) deemed safe and efficacious by the US FDA

KEYWORDS:

Jean-Guillaume Lecomte

AOP's neurology focus

Dr. Georg Fischer, AOP

narcolepsy

Dr. Rudolf Widmann

European Medicines Agency (EMA)

Wakix®

Bioprojet Pharma SAS

Wakix® (pitolisant)

AOP ORPHAN

Download Photos

[ Download Photos ]

attachments to announcement

AOP Orphan and Bioprojet Pharma SAS entered a distribution agreement for Wakix®

back to announcement

photos

[ download press photo ]

title: AOP Orphan Pharmaceuticals AG
image text: AOP Orphan will distribute Wakix® (pitolisant) from Bioprojet Pharma SAS in Austria, Nordic countries and Central Eastern Europe.
copyright: AOP Orphan

PRESS BOX Interactive

News Releases via
RSS-Feed

Subscribe
News Releases

Create digital
Press Folder (pdf)

Embedd News Releases
in your Webseite

Social Media